Humana (NYSE:HUM) had its price target decreased by Credit Suisse Group from $390.00 to $352.00 in a research report released on Thursday, The Fly reports. Credit Suisse Group currently has an outperform rating on the insurance provider’s stock.

HUM has been the topic of a number of other reports. raised their target price on shares of Humana from $350.00 to $373.00 and gave the stock an outperform rating in a research report on Thursday, November 8th. Stephens assumed coverage on shares of Humana in a research report on Monday, January 14th. They set an overweight rating and a $336.00 target price on the stock. Zacks Investment Research lowered shares of Humana from a buy rating to a hold rating in a research report on Thursday, December 13th. Jefferies Financial Group lifted their price objective on shares of Humana from $388.00 to $410.00 and gave the company a buy rating in a research report on Thursday, November 8th. Finally, Cowen upgraded shares of Humana from a market perform rating to an outperform rating and set a $275.02 price objective on the stock in a research report on Friday, January 11th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Humana currently has a consensus rating of Buy and an average price target of $355.06.

HUM stock opened at $298.89 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.68 and a current ratio of 1.68. The company has a market cap of $41.00 billion, a price-to-earnings ratio of 20.54, a P/E/G ratio of 1.23 and a beta of 1.05. Humana has a twelve month low of $261.13 and a twelve month high of $355.88.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 6th. The insurance provider reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.12. The business had revenue of $14.17 billion for the quarter, compared to analyst estimates of $14.04 billion. Humana had a net margin of 2.96% and a return on equity of 19.64%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period last year, the firm posted $2.06 earnings per share. As a group, analysts predict that Humana will post 17.48 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. This is a positive change from Humana’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Thursday, March 28th. Humana’s dividend payout ratio (DPR) is 6.87%.

In other Humana news, Director David A. Jr/Ky Jones sold 600 shares of the business’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $88.05, for a total transaction of $52,830.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Heidi S. Margulis sold 2,656 shares of the business’s stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $296.22, for a total transaction of $786,760.32. Following the sale, the insider now owns 10,371 shares in the company, valued at $3,072,097.62. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Moody National Bank Trust Division purchased a new stake in shares of Humana during the 4th quarter worth $30,000. Proficio Capital Partners LLC boosted its position in shares of Humana by 81.4% during the 4th quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 48 shares in the last quarter. We Are One Seven LLC purchased a new stake in shares of Humana during the 4th quarter worth $31,000. Exane Asset Management purchased a new stake in shares of Humana during the 4th quarter worth $43,000. Finally, Athena Capital Advisors LLC purchased a new stake in shares of Humana during the 4th quarter worth $57,000. Institutional investors own 95.63% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Further Reading: The risks of owning bonds

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.